Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000947871-26-000114·MBX Biosciences, Inc.
Schedule 13D ownership disclosure
MBX Biosciences Inc
COMMON STOCK · CUSIP: 55287L101
Event date: 2026-02-05
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ORBIMED ADVISORS LLCReported CIK 0001055951
Shares: 3,637,887.00 · Class: 7.7%
- ORBIMED CAPITAL GP VII LLCReported CIK 0001760648
Shares: 2,958,000.00 · Class: 6.3%
- OrbiMed Genesis GP LLCReported CIK 0001808744
Shares: 679,887.00 · Class: 1.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-26-000114
- Form type
- SCHEDULE 13D/A
- Filer
- MBX Biosciences, Inc.
- CIK
- CIK 1776111
- Filed
- Feb 11, 2026
- Reporting period
- Feb 05, 2026
- Description
- Schedule 13D beneficial ownership